Pimavanserin for the treatment of Parkinson's disease psychosis
@article{Friedman2013PimavanserinFT, title={Pimavanserin for the treatment of Parkinson's disease psychosis}, author={Joseph H. Friedman}, journal={Expert Opinion on Pharmacotherapy}, year={2013}, volume={14}, pages={1969 - 1975} }
Introduction: Parkinson's disease (PD) is a neurobehavioral disorder defined by its motor features. Its treatment is frequently complicated by the presence of psychotic symptoms, most prominently hallucinations and delusions. These cause major distress and are the primary cause for nursing home placement. Current treatment requires either a reduction in medications for mobility or the addition of atypical antipsychotics, none of which are approved in the United States, and which are associated…
12 Citations
Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review
- Medicine, PsychologyClinical neuropharmacology
- 2018
Almost 50% of parkinsonian patients with psychotic symptoms found Pim to be a useful medication, which they continue to take, according to a chart review of all patients started on the drugs since the one earlier report.
Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
- Medicine, PsychologyParkinsonism & related disorders
- 2019
A Novel Synthesis of Pimavanserin: A Selective Serotonin 5-HT2A Receptor Inverse Agonist
- Chemistry
- 2020
Psychosis in patients with Parkinson’s disease (PD) is a common, at times debilitating, condition and represents a major unmet need in the treatment of PD. Pimavanserin…
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
- Psychology, MedicineCNS Drugs
- 2020
The evidence for the role of the serotonin type 2A receptor (5-HT2AR) in schizophrenia is assessed and Food and Drug Administration (FDA)-approved and investigational 5- HT2AR-modulating compounds are reviewed.
Antipsychotic drugs and sudden cardiac death: A literature review of the challenges in the prediction, management, and future steps
- Medicine, PsychologyPsychiatry Research
- 2019
(11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand.
- BiologyBioorganic & medicinal chemistry letters
- 2015
PET Imaging of the 5-HT 2A Receptor System: A Tool to Study the Receptor’s In Vivo Brain Function
- Psychology, Biology
- 2018
The serotonergic 5-HT2A receptor system plays a key modulatory role for many brain functions such as regulation of mood, temperature, sex, appetite and emotions and makes it an obvious target for many drugs.
Investigation of metabolic profile of pimavanserin in rats by ultrahigh-performance liquid chromatography combined with Fourier transform ion cyclotron resonance mass spectrometry.
- Chemistry, BiologyRapid communications in mass spectrometry : RCM
- 2018
This report presents the first study of screening and identification of the metabolites of pimavanserin, a promising candidate for treating Parkinson's disease psychosis, using the UHPLC/FT-ICR-MS method, a powerful tool for exploring and identifying metabolites in complex biological samples.
5-HT2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives.
- Chemistry, BiologyEuropean journal of medicinal chemistry
- 2016
Quantification of Pimavanserin in Bulk and Tablet Dosage Form Using A Stability Indicating High Performance Liquid Chromatographic Method
- MedicinePharmaceutical Sciences
- 2018
A new sensitive, precise and accurate stability indicating reverse phase HPLC method with photodiode array detector has been developed and validated and is able to quantify the pimavanserin in the presence of degradation products.
References
SHOWING 1-10 OF 50 REFERENCES
Aripiprazole associated with severe exacerbation of Parkinson's disease
- Psychology, MedicineMovement disorders : official journal of the Movement Disorder Society
- 2006
Aripiprazole is a novel atypical antipsychotic with an apparently unique mechanism of action—a dopamine system stabilizer with partial agonist effect at D2 and 5HT1a receptors that would treat psychotic symptoms in Parkinson’s disease with fewer extrapyramidal side effects.
Parkinson Disease Psychosis: Update
- Psychology, MedicineBehavioural neurology
- 2013
Only clozapine has level A evidence to support its use in PD patients with psychosis (PDP), whether demented or not, and other antipsychotic drugs have been reported to worsen motor function and data on the effectiveness of cholinesterase inhibitors is limited.
Parkinson's disease: The quintessential neuropsychiatric disorder
- Psychology, MedicineMovement disorders : official journal of the Movement Disorder Society
- 2011
The emergent focus on nonmotor aspects of Parkinson's disease over the past quarter of a century is highlighted by a nonlinear increase in the number of articles published devoted to this topic.
Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
- Psychology, MedicineNeuropsychopharmacology
- 2010
Pimavanserin showed significantly greater improvement in psychosis in patients with PDP at a dose which did not impair motor function, or cause sedation or hypotension, which support the hypothesis that attenuation of psychosis secondary to DA receptor stimulation in PDP may be achieved through selective 5-HT2A receptor antagonism.
Epidemiology of psychosis in Parkinson's disease
- Psychology, MedicineJournal of the Neurological Sciences
- 2010
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
- Psychology, MedicineMovement disorders : official journal of the Movement Disorder Society
- 2007
It is suggested that PDPsy may result from progression of the disease process underlying PD, rather than a comorbid psychiatric disorder or drug intoxication, and are a potential indication for therapy development.
Psychiatric syndromes in Parkinson's disease
- Psychology, MedicineCurrent opinion in psychiatry
- 2012
Standardized criteria should be used to diagnose depression and apathy in Parkinson's disease and psychotherapy and pharmacotherapy are useful treatment modalities for affective disorders in Parkinson’s disease.
Drug-Induced Psychosis in Parkinson Disease: Phenomenology and Correlations Among Psychosis Rating Instruments
- Psychology, MedicineClinical neuropharmacology
- 2005
Nonvisual hallucinations and delusions may occur more frequently in DIP than previously thought and these symptoms, plus agitation and hostility, may ultimately be the best measure of DIP in patients with PD.
Aripiprazole for Drug-Induced Psychosis in Parkinson Disease: Preliminary Experience
- Psychology, MedicineClinical neuropharmacology
- 2004
The preliminary experience in 8 patients with probable Parkinson disease treated with aripiprazole for drug-induced psychosis is mixed but not very encouraging, and controlled studies are needed to evaluate aripIPrazole in parkinsonian patients.
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease
- Psychology, BiologyBehavioural pharmacology
- 2011
Pimavanserin, a selective 5- HT2A antagonist/inverse agonist, reversed the psychotic-like behavioral deficits, suggesting that nigrostriatal (6-hydroxydopamine) lesions induced alterations in 5-HT2A-mediated signaling.